HLA-G molecules in autoimmune diseases and infections

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Rizzo, Roberta ^a   Bortolotti, Daria ^a   Bolzani, Silvia ^a   Fainardi, Enrico ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Autoimmunity; HLA G; Infection; Inflammation; Regulation

Indexed keywords

B LYMPHOCYTE DIFFERENTIATION FACTOR; HLA DQ2 ANTIGEN; HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN LIKE TRANSCRIPT 2; IMMUNOGLOBULIN LIKE TRANSCRIPT 4; INTERLEUKIN 10; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CROHN DISEASE; DENDRITIC CELL; DIABETES MELLITUS; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MONONUCLEAR CELL; MRNA EXPRESSION ASSAY; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 84918774501     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00592     Document Type: Review

References (161)

1. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol (2008) 29:125-32. doi: 10.1016/j.it.2007.11.005
2. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood (2008) 111:4862-70. doi:10.1182/blood-2007-12-127662
3. Ishitani A, Gerarthy DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci U S A (1992) 89:3947-51. doi:10.1073/pnas.89.9.3947
4. Paul P, Cabestre FA, Ibrahim EC, Lefevbre S, Khalil-Daher I, Vazeux G, et al. Identification of HLA-G7 as a new slice variant of the HLA-G mRNA and expression of soluble HL-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol (2000) 61:1138-49. doi:10.1016/S0198-8859(00)00197-X
5. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science (1990) 144:220-3. doi:10.1126/science.2326636
6. Larsen MH, Hviid TV. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum Immunol (2009) 70:1026-34. doi:10.1016/j.humimm.2009.07.015
7. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in plasma in relation to HLA-G genotype and polymorphisms. Immunogenetics (2004) 56:135-41. doi:10.1007/s00251-004-0673-2
8. Yan WH, Lin A, Chen XJ, Dai MZ, Gan LH, Zhou MY, et al. Association of the maternal 14-bp insertion polymorphism in the HLA-G gene in women with recurrent spontaneous abortions. Tissue Antigens (2006) 68:521-3. doi:10.1111/j.1399-0039.2006.00723.x
9. Hviid TV, Christiansen OB. Linkage disequilibrium between human leukocyte antigen (HLA) class II and HLA-G - possible implications for human reproduction and autoimmune disease. Hum Immunol (2005) 66:688-99. doi:10.1016/j.humimm.2005.03.00310.
10. Veit TD, Chies JAB. Tolerance versus immune response microRNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol (2009) 20:229-31. doi:10.1016/j.trim.2008.11.001
11. LeMaoult J, Le Discorde M, Rouas-Freiss N, Moreau P, Menier C, McCluskey J, et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens (2003) 62:273-84. doi:10.1034/j.1399-0039.2003.00143.
12. Park GM, Lee S, Park B, Kim E, Shin J, Cho K, et al. Soluble HLA-G generated by proteolytic shedding inhibits NKmediated cell lysis. Biochem Biophys Res Commun (2004) 313:606-11. doi:10.1016/j.bbrc.2003.11.153
13. Dong Y, Lieskovska J, Kedrin D, Porcelli S, Mandelboim O, Bushkin Y. Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol (2003) 64:802-10. doi:10.1016/S0198-8859(03)00093-4
14. Demaria S, Schwab R, Gottesman SRS, Bushkin Y. Soluble b2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem (1994) 269:6689-94.
15. Zidi I, Guillard C, Marcou C, Krawice-Radanne I, Sangrouber D, Rouas-Freiss N, et al. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci (2006) 63:2669-81. doi:10.1007/s00018-006-6341-y
16. Rizzo R, Trentini A, Bortolotti D, Manfrinato MC, Rotola A, Castellazzi M, et al. Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Mol Cell Biochem (2013) 381:243-55. doi:10.1007/s11010-013-1708-5
17. Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, Moses E, et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci U S A (2005) 102:3360-5. doi:10.1073/pnas.0409676102
18. Juch H, Blaschitz A, Daxböck C, Rueckert C, Kofler K, Dohr G. A novel sandwich ELISA for alpha1 domain based detection of soluble HLA-G heavy chains. J Immunol Methods (2005) 307:96-106. doi:10.1016/j.jim.2005.09.016
19. Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, et al. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A (2002) 99:16180-5. doi:10.1073/pnas.212643199
20. Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol (2003) 171:1343-51. doi:10.4049/jimmunol.171.3.1343
21. Favier B, HoWangYin KY, Wu J, Caumartin J, Daouya M, Horuzsko A, et al. Tolerogenic function of dimeric forms of HLA-G recombinant proteins: a comparative study in vivo. PLoS One (2011) 6:e21011. doi:10.1371/journal.pone.0021011
22. Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol (2007) 37:1924-37. doi:10.1002/eji.200737089
23. Zilberman S, Schenowitz C, Agaugué S, Benoît F, Riteau B, Rouzier R, et al. HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment. Eur J Immunol (2012) 42:1599-608. doi:10.1002/eji.201141761
24. Ellis SA, Palmer LS, McMichael AJ. Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA class I molecule. J Immunol (1990) 144:731-5.
25. Mallet V, Blaschitz A, Crisa L, Schmitt C, Fournel S, King A, et al. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int Immunol (1999) 11:889-98. doi:10.1093/intimm/11.6.889
26. Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol (2003) 64:1039-44. doi:10.1016/j.humimm.2003.08.346
27. Ito T, Ito N, Saathoff M, Stampachiacchiere B, Bettermann A, Bulfone-Paus S, et al. Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol (2005) 125:1139-48. doi:10.1111/j.0022-202X.2005.23927.x
28. Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, et al. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes (2006) 55:1214-22. doi:10.2337/db05-0731
29. Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood (2004) 104:3153-60. doi:10.1182/blood-2004-03-0809
30. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol (1999) 11:803-11. doi:10.1093/intimm/11.5.803
31. Rizzo R, Melchiorri L, Stignani M, Baricordi OR. HLA-G expression is a fundamental prerequisite to pregnancy. Hum Immunol (2007) 68:244-50. doi:10.1016/j.humimm.2006.10.012
32. Lila N, Amrein C, Guillemain R, Chevalier P, Latremouille C, Fabiani JN, et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation (2002) 105:1949-54. doi:10.1161/01.CIR.0000015075.89984.46
33. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol (2007) 17:469-79. doi:10.1016/j.semcancer.2007.07.004
34. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 95:4510-5. doi:10.1073/pnas.95.8.4510
35. Onno M, Pangault C, Le Friec G, Guilloux V, Andre P, Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol (2000) 164:6426-34. doi:10.4049/jimmunol.164.12.6426
36. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The a1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci U S A (1997) 94:5249-54. doi:10.1073/pnas.94.10.5249
37. Fournel S, Aguerre-Gi M, Huc X, Lenfant F, Alam A, Toubert A, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD 95 ligand-mediated apoptosis in activated CD8+ cells by interacting CD8. J Immunol (2000) 164:6100-4. doi:10.4049/jimmunol.164.12.6100
38. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, et al. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol (2003) 33:125-34. doi:10.1002/immu.200390015
39. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc. Natl Acad Sci U S A (2001) 98:12150-5. doi:10.1073/pnas.201407398
40. Le Rond S, Azèma C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella ED, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol (2006) 176:3266-76. doi:10.4049/jimmunol.176.5.3266
41. Horuzsko A, Lenfant F, Munn DH, Mellor AL. Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice. Int Immunol (2001) 13:385-94. doi:10.1093/intimm/13.3.385
42. Colonna M, Navarro F, Bellón T, Llano M, García P, Samaridis J, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med (1997) 186:1809-18. doi:10.1084/jem.186.11.1809
43. Kanai T, Fujii T, Kozuma S, Yamashita T, Miki A, Kikuchi A, et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod (2001) 7:195-200. doi:10.1093/molehr/7.2.195
44. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood (2007) 109:2040-8. doi:10.1182/blood-2006-05-024547
45. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 11:935-44. doi:10.1182/blood-2009-07-234872
46. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J (2005) 19:662-4. doi:10.1096/fj.04-1617fje
47. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol (2001) 22:553-5. doi:10.1016/S1471-4906(01)02007-5
48. Rizzo R, Bortolotti D, Baricordi OR, Fainardi E. New insights into HLA-G and inflammatory diseases. Inflamm Allergy Drug Targets (2012) 11:448-63. doi:10.2174/187152812803590037
49. Torres MI, López-Casado MA, Luque J, Peña J, Ríos A. New advances in coeliac disease: serum and intestinal expression of HLA-G. Int Immunol (2006) 18:713-8. doi:10.1093/intimm/dxl008
50. Fabris A, Segat L, Catamo E, Morgutti M, Vendramin A, Crovella S. HLA-G 14 bp deletion/insertion polymorphism in celiac disease. Am J Gastroenterol (2011) 106:139-44. doi:10.1038/ajg.2010.340
51. Rizzo R, Melchiorri L, Simone L, Stignani M, Marzola A, Gullini S, et al. Different production of soluble HLA-G antigens by peripheral blood mononuclear cells in ulcerative colitis and Crohn's disease: a noninvasive diagnostic tool? Inflamm Bowel Dis (2008) 14:100-5. doi:10.1002/ibd.20281
52. Zelante A, Borgoni R, Galuppi C, Cifalà V, Melchiorri L, Gullini S, et al. Therapy modifies HLA-G secretion differently in Crohn's disease and ulcerative colitis patients. Inflamm Bowel Dis (2011) 17:E94-5. doi:10.1002/ibd.21756
53. Lee HM, Sugino H, Aoki C, Shimaoka Y, Suzuki R, Ochi K, et al. Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis. Arthritis Res Ther (2011) 13:R89. doi:10.1186/ar3364
54. Veit TD, Vianna P, Scheibel I, Brenol CV, Brenol JC, Xavier RM, et al. Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis. Tissue Antigens (2008) 71:440-6. doi:10.1111/j.1399-0039.2008.01019.x
55. Kim SK, Chung JH, Kim DH, Yun DH, Hong SJ, Lee KH. Lack of association between promoter polymorphisms of HLA-G gene and rheumatoid arthritis in Korean population. Rheumatol Int (2012) 32:509-12. doi:10.1007/s00296-010-1735-4
56. Catamo E, Addobbati C, Segat L, Sotero Fragoso T, Domingues Barbosa A, Tavares Dantas A, et al. HLA-G gene polymorphisms associated with susceptibility to rheumatoid arthritis disease and its severity in Brazilian patients. Tissue Antigens (2014) 84:308-15. doi:10.1111/tan.12396
57. Verbruggen LA, Rebmann V, Demanet C, De Cock S, Grosse-Wilde H. Soluble HLA-G in rheumatoid arthritis. Hum Immunol (2006) 67:561-7. doi:10.1016/j.humimm.2006.03.023
58. Prigione I, Penco F, Martini A, Gattorno M, Pistoia V, Morandi F. HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology (2011) 50:966-72. doi:10.1093/rheumatology/keq418
59. Ongaro A, Stignani M, Pellati A, Melchiorri L, Massari L, Caruso G, et al. Human leukocyte antigen-G molecules are constitutively expressed by synovial fibroblasts and upmodulated in osteoarthritis. Hum Immunol (2010) 71:342-50. doi:10.1016/j.humimm.2010.01.015
60. Rudwaleit M, Yin Z, Siegert S, Grolms M, Radbruch A, Braun J, et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis (2000) 59:311-4. doi:10.1136/ard.59.4.311
61. Rizzo R, Hviid TV, Stignani M, Balboni A, Grappa MT, Melchiorri L, et al. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics (2005) 57:172-81. doi:10.1007/s00251-005-0788-0
62. Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri L, Stignani M, et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics (2006) 16:615-23. doi:10.1097/01.fpc.0000230115.41828.3a
63. Stamp LK, O'Donnell JL, Chapman PT, Barclay ML, Kennedy MA, Frampton CM, et al. Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis. Ann Rheum Dis (2009) 68:154-5. doi:10.1136/ard.2008.089383
64. Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics (2010) 11:163-75. doi:10.2217/pgs.09.139
65. Needleman BW. Immunologic aspects of scleroderma. Curr Opin Rheumatol (1992) 4:862-8.
66. Wastowski IJ, Sampaio-Barros PD, Amstalden EM, Palomino GM, Marques-Neto JF, Crispim JC, et al. HLA-G expression in the skin of patients with systemic sclerosis. J Rheumatol (2009) 36:1230-4. doi:10.3899/jrheum.080552
67. Rosado S, Perez-Chacon G, Mellor-Pita S, Sanchez-Vegazo I, Bellas-Menendez C, Citores MJ, et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol (2008) 69:9-15. doi:10.1016/j.humimm.2007.11.001
68. Chen J, Shen B, Jiang Y, Jun L, Zhu M, Chen B, et al. Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients. Clin Exp Med (2013) 13:135-42. doi:10.1007/s10238-012-0185-6
69. Rizzo R, Hviid TV, Govoni M, Padovan M, Rubini M, Melchiorri L, et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens (2008) 71:520-9. doi:10.1111/j.1399-0039.2008.01037.x
70. Rudstein-Svetlicky N, Loewenthal R, Horejsi V, Gazit E. HLA-G levels in serum and plasma. Tissue Antigens (2007) 69(Suppl 1):140-2. doi:10.1111/j.1399-0039.2006.763_4.x
71. Monsiváis-Urenda AE, Baranda L, Alvarez-Quiroga C, Abud-Mendoza C, González-Amaro R. Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus. J Clin Immunol (2011) 31:369-78. doi:10.1007/s10875-010-9496-0
72. Fernando MM, Freudenberg J, Lee A, Morris DL, Boteva L, Rhodes B, et al. Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. Ann Rheum Dis (2012) 71:777-84. doi:10.1136/annrheumdis-2011-200808
73. Veit TD, Cordero EA, Mucenic T, Monticielo OA, Brenol JC, Xavier RM, et al. Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus. Lupus (2009) 18:424-30. doi:10.1177/0961203308098187
74. Pedroza LS, Sauma MF, Vasconcelos JM, Takeshita LY, Ribeiro-Rodrigues EM, Sastre D, et al. Systemic lupus erythematosus: association with KIR and SLC11A1 polymorphisms, ethnic predisposition and influence in clinical manifestations at onset revealed by ancestry genetic markers in an urban Brazilian population. Lupus (2011) 20:265-73. doi:10.1177/0961203310385266
75. Lucena-Silva N, de Souza VS, Gomes RG, Fantinatti A, Muniz YC, de Albuquerque RS, et al. HLA-G 3' untranslated region polymorphisms are associated with systemic lupus erythematosus in 2 Brazilian populations. J Rheumatol (2013) 40:1104-13. doi:10.3899/jrheum.120814
76. Consiglio CR, Veit TD, Monticielo OA, Mucenic T, Xavier RM, Brenol JC, et al. Association of the HLA-G gene +3142C >G polymorphism with systemic lupus erythematosus. Tissue Antigens (2011) 77:540-5. doi:10.1111/j.1399-0039.2011.01635.x
77. Park KS, Nam JH, Lee ES, Choi JS, Bang D, Lee S. Increased risk of human leukocyte antigen-G gene variants in Behçet's disease. Clin Exp Rheumatol (2006) 24(5 Suppl 42):S126-7.
78. Park KS, Park JS, Nam JH, Bang D, Sohn S, Lee ES. HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease. Tissue Antigens (2007) 69:139-44. doi:10.1111/j.1399-0039.2006.00742.x
79. Kim JJ, Hong SJ, Hong YM, Kim S, Kang MJ, Kim KJ, et al. Genetic variants in the HLA-G region are associated with Kawasaki disease. Hum Immunol (2008) 69:867-71. doi:10.1016/j.humimm.2008.10.002
80. Bos JD. Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology. 3rd ed. Boca Raton, FL: CRC Press (2005). p. 77-99.
81. Ulbrecht M, Rehberger B, Strobel I, Messer G, Kind P, Degitz K, et al. HLA-G: expression in human keratinocytes in vitro and in human skin in vivo. Eur J Immunol (1994) 24:176-80. doi:10.1002/eji.1830240127
82. Cardili RN, Alves TG, Freitas JC, Soares CP, Mendes-Junior CT, Soares EG, et al. Expression of human leucocyte antigen-G primarily targets affected skin of patients with psoriasis. Br J Dermatol (2010) 63(4):769-75. doi:10.1111/j.1365-2133.2010.09917.x
83. Urosevic M, Kamarashev J, Burg G, Dummer R. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer cell inhibitory ligand, ILT2. Blood (2004) 103:1796-8. doi:10.1182/blood-2003-10-3372
84. Urosevic M, Kempf W, Zagrodnik B, Panizzon R, Burg G, Dummer R. HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. Clin Exp Dermatol (2005) 30:422-5. doi:10.1111/j.1365-2230.2005.01790.x
85. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLAG protein up-regulation in primary cutaneous lymphomas is associated with IL-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood (2002) 99:609-17. doi:10.1182/blood.V99.2.609
86. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med (1999) 341:1817-28. doi:10.1056/NEJM199912093412407
87. Sweeney C, Kirby B. Does HLA-G prevent tissue destruction in psoriasis? Br J Dermatol (2011) 164:1118-9. doi:10.1111/j.1365-2133.2011.10222.x
88. Borghi A, Fogli E, Stignani M, Melchiorri L, Altieri E, Baricordi OR, et al. Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease. Arch Dermatol Res (2008) 300:551-9. doi:10.1007/s00403-008-0886-6
89. Borghi A, Rizzo R, Corazza M, Bertoldi AM, Bortolotti D, Sturabotti G, et al. HLA-G 14-bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study. Dermatol Ther (2014) 27:284-9. doi:10.1111/dth.12140
90. Yari F, Zavaran Hosseini A, Nemat Gorgani M, Khorramizadeh MR, Mansouri P, Kazemnejad A. Expression of HLA-G in the skin of patients with pemphigus vulgaris. Iran J Allergy Asthma Immunol (2008) 7:7-12. doi:07.01/ijaai.712
91. Gazit E, Slomov Y, Goldberg I, Brenner S, Loewenthal R. HLA-G is associated with pemphigus vulgaris in Jewish patients. Hum Immunol (2004) 65:39-46. doi:10.1016/j.humimm.2003.09.019
92. Solini A, Muscelli E, Stignani M, Melchiorri L, Santini E, Rossi C, et al. Soluble human leukocyte antigen-g expression and glucose tolerance in subjects with different degrees of adiposity. J Clin Endocrinol Metab (2010) 95:3342-6. doi:10.1210/jc.2009-2747
93. Eike MC, Becker T, Humphreys K, Olsson M, Lie BA. Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun (2009) 10:56-67. doi:10.1038/gene.2008.74
94. Abediankenari S, Eslami MB, Sarrafnejad A, Mohseni M, Larijani B. Dendritic cells bearing HLA-G inhibit T-Cell activation in type 1 diabetes. Iran J Allergy Asthma Immunol (2007) 6:1-7.
95. García-González IJ, Valle Y, Rivas F, Figuera-Villanueva LE, Muñoz-Valle JF, Flores-Salinas HE, et al. The 14 bp Del/Ins HLA-G polymorphism is related with high blood pressure in acute coronary syndrome and type 2 diabetes mellitus. Biomed Res Int (2014) 2014:898159. doi:10.1155/2014/898159
96. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol (2009) 9:393-407. doi:10.1038/nri2550
97. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med (2000) 43:938-52. doi:10.1056/NEJM200009283431307
98. Compston A, Coles A. Multiple sclerosis. Lancet (2008) 372:1502-17. doi:10.1016/S0140-6736(08)61620-7
99. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 69:292-302. doi:10.1002/ana.22366
100. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest (2012) 122:1180-8. doi:10.1172/JCI58649
101. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron (2006) 52:61-76. doi:10.1016/j.neuron.2006.09.011
102. Fainardi E, Rizzo R, Castellazzi M, Stignani M, Granieri E, Baricordi OR. Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis. Hum Immunol (2009) 70:981-7. doi:10.1016/j.humimm.2009.07.014
103. Fainardi E, Castellazzi M, Stignani M, Morandi F, Sana G, Gonzalez R, et al. Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci (2011) 68:433-51. doi:10.1007/s00018-010-0584-3
104. Fainardi E, Rizzo R, Melchiorri L, Vaghi L, Castellazzi M, Marzola A, et al. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. J Neuroimmunol (2003) 142:149-58. doi:10.1016/S0165-5728(03)00266-2
105. Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Paolino E, Tola MR, et al. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult Scler (2006) 12:2-12. doi:10.1191/1352458506ms1241oa
106. Fainardi E, Rizzo R, Melchiorri L, Stignani M, Castellazzi M, Caniatti ML, et al. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol (2007) 192:219-25. doi:10.1016/j.jneuroim.2007.10.002
107. Fainardi E, Rizzo R, Melchiorri L, Stignani M, Castellazzi M, Tamborino C, et al. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing remitting multiple sclerosis. Mult Scler (2008) 14:446-54. doi:10.1177/1352458507085137
108. Mitsdoerffer M, Schreiner B, Kieseier B, Neuhaus O, Dichgans J, Hartung H-P, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-ß in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol (2005) 159:155-64. doi:10.1016/j.jneuroim.2004.09.016
109. Airas L, Nikula T, Huang Y-H, Lahesmaa R, Wiendl H. Post-partum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. J Neuroimmunol (2007) 187:205-11. doi:10.1016/j.jneuroim.2007.05.008
110. Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain (2005) 128:2689-704. doi:10.1093/brain/awh609
111. Feger U, Tolosa E, Huang Y-H, Waschbisch A, Biedermann T, Melms A, et al. HLA-G expression defines a novel regulatory T cell subset present in human peripheral blood and sites of inflammation. Blood (2007) 110:568-77. doi:10.1182/blood-2006-11-057125
112. Huang YH, Zozulya AL, Weidenfeller C, Schwab N, Wiendl H. T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. J Leukoc Biol (2009) 86:273-81. doi:10.1189/jlb.1008649
113. Huang YH, Zozulya AL, Weidenfeller C, Metz I, Buck D, Toyka KV, et al. Specific central nervous system recruitment of HLA-G (+) regulatory T cells in multiple sclerosis. Ann Neurol (2009) 66:171-83. doi:10.1002/ana.21705
114. Cree BA, Rioux JD, McCauley JL, Gourraud PA, Goyette P, McElroy J, et al. A major histocompatibility class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS One (2010) 5:e11296. doi:10.1371/journal.pone.0011296
115. Kroner A, Grimm A, Johannssen K, Mäurer M, Wiendl H. The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis. Hum Immunol (2007) 68:422-5. doi:10.1016/j.humimm.2007.01.012
116. Wisniewski A, Bilinska M, Klimczak A, Wagner M, Majorczyk E, Nowak I, et al. Association of the HLA-G gene polymorphism with multiple sclerosis in a polish population. Int J Immunogenet (2010) 37:307-11. doi:10.1111/j.1744-313X.2010.00926.x
117. Rizzo R, Bortolotti D, Fredj NB, Rotola A, Cura F, Castellazzi M, et al. Role of HLA-G 14bp deletion/insertion and +3142C >G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. Hum Immunol (2012) 73:1140-6. doi:10.1016/j.humimm.2012.08.005
118. Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L, et al. Beneficial effect of interferon-ß 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. J Neuroimmunol (2004) 148:206-11. doi:10.1016/j.jneuroim.2003.12.002
119. Waschbisch A, Sandbrink R, Hartung HP, Kappos L, Schwab S, Pohl C, et al. Evaluation of soluble HLA-G as a biomarker for multiple sclerosis. Neurology (2011) 77:596-8. doi:10.1212/WNL.0b013e318228c14d
120. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol (2000) 8:410-8. doi:10.1016/S0966-842X(00)01830-8
121. Tripathi P, Agrawal S. The role of human leukocyte antigen E and G in HIV infection. AIDS (2007) 21:1395-404. doi:10.1097/QAD.0b013e32810c8bbc
122. Lozano JM, Gonzalez R, Kindelan JM, Rouas-Freiss N, Caballos R, Dausset J, et al. Monocytes and T-lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS (2002) 16:347-51. doi:10.1097/00002030-200202150-00005
123. Cabello A, Rivero A, Garcia MJ, Lozano JM, Torre-Cisneros J, Gonzalez R, et al. HAART induces the expression of HLA-G on peripheral monocytes in HIV-1 infected individuals. Hum Immunol (2003) 64:1045-9. doi:10.1016/j.humimm.2003.08.353
124. Li C, Toth I, Schulze Zur Wiesch J, Pereyra F, Rychert J, Rosenberg ES, et al. Functional characterization of HLA-G+ regulatory T cells in HIV-1 infection. PLoS Pathog (2013) 9:e1003140. doi:10.1371/journal.ppat.1003140
125. da Silva GK, Vianna P, Veit TD, Crovella S, Catamo E, Cordero EA, et al. Influence of HLA-G polymorphisms in human immunodeficiency virus infection and hepatitis C virus co-infection in Brazilian and Italian individuals. Infect Genet Evol (2014) 21:418-23. doi:10.1016/j.meegid.2013.12.013
126. Segat L, Zupin L, Kim HY, Catamo E, Thea DM, Kankasa C, et al. HLA-G 14bp deletion/insertion polymorphism and mother-to-child transmission of HIV. Tissue Antigens (2014) 83:161-7. doi:10.1111/tan.12296
127. Soderberg-Naucler C, Nelson JY. Human cytomegalovirus latency and reactivation - a delicate balance between the virus and its host's immune system. Intervirology (1999) 42:314-21. doi:10.1159/000053966
128. Yan WH, Lin A, Chen BG, Chen SY. Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. J Infect Dis (2009) 200:820-6. doi:10.1086/604733
129. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol (2002) 76:1285-92. doi:10.1128/JVI.76.3.1285-1292.2002
130. Xu HH, Shi WW, Lin A, Yan WH. HLA-G 3' untranslated region polymorphisms influence the susceptibility for human papillomavirus infection. Tissue Antigens (2014) 84(2):216-22. doi:10.1111/tan.12359
131. Smith MA, Tellier PP, Roger M, Coutlée F, Franco EL, Richardson H. Determinants of human papillomavirus coinfections among Montreal university students: the influence of behavioral and biologic factors. Cancer Epidemiol Biomarkers Prev (2014) 23(5):812-22. doi:10.1158/1055-9965.EPI-13-1255
132. Metcalfe S, Roger M, Faucher MC, Coutlée F, Franco EL, Brassard P. The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec. Hum Immunol (2013) 74(12):1610-5. doi:10.1016/j.humimm.2013.08.279
133. Silva ID, Muniz YC, Sousa MC, Silva KR, Castelli EC, Filho JC, et al. HLA-G 3'UTR polymorphisms in high grade and invasive cervico-vaginal cancer. Hum Immunol (2013) 74(4):452-8. doi:10.1016/j.humimm.2012.11.025
134. Dong DD, Yang H, Li K, Xu G, Song LH, Fan XL, et al. Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response. Reprod Sci (2010) 17(8):718-23. doi:10.1177/1933719110369183
135. Simões RT, Gonçalves MA, Castelli EC, Júnior CM, Bettini JS, Discorde ML, et al. HLA-G polymorphisms in women with squamous intraepithelial lesions harboring human papillomavirus. Mod Pathol (2009) 22(8):1075-82. doi:10.1038/modpathol.2009.67
136. Guimarães MC, Soares CP, Donadi EA, Derchain SF, Andrade LA, Silva TG, et al. Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). J Histochem Cytochem (2010) 58(5):405-11. doi:10.1369/jhc.2009.954131
137. Yang YC, Chang TY, Chen TC, Lin WS, Chang SC, Lee YJ. Human leucocyte antigen-G polymorphisms are associated with cervical squamous cell carcinoma risk in Taiwanese women. Eur J Cancer (2014) 50(2):469-74. doi:10.1016/j.ejca.2013.10.018
138. Bortolotti D, Gentili V, Rotola A, Di Luca D, Rizzo R. Implication of HLA-G 3' untranslated region polymorphisms in human papillomavirus infection. Tissue Antigens (2014) 83(2):113-8. doi:10.1111/tan.12281
139. Rodríguez JA, Galeano L, Palacios DM, Gómez C, Serrano ML, Bravo MM, et al. Altered HLA class I and HLA-G expression is associated with IL-10 expression in patients with cervical cancer. Pathobiology (2012) 79:72-83. doi:10.1159/000334089
140. Gillio-Tos A, Bicalho Mda G, Fiano V, Grasso C, Tarallo V, De Marco L, et al. Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis. BMC Cancer (2012) 12:618. doi:10.1186/1471-2407-12-618
141. Rizzo R, Malagutti N, Bortolotti D, Gentili V, Rotola A, Fainardi E, et al. Infection and HLA-G molecules in nasal polyposis. J Immunol Res (2014) 2014:407430. doi:10.1155/2014/407430
142. Mégret F, Prehaud C, Lafage M, Moreau P, Rouas-Freiss N, Carosella ED, et al. Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. Hum Immunol (2007) 68:294-302. doi:10.1016/j.humimm.2006.12.003
143. Cordero EA, Veit TD, da Silva MA, Jacques SM, Silla LM, Chies JA. HLA-G polymorphism influences the susceptibility to HCV infection in sickle cell disease patients. Tissue Antigens (2009) 74:308-13. doi:10.1111/j.1399-0039.2009.01331.x
144. Weng PJ, Fu YM, Ding SX, Xu DP, Lin A, Yan WH. Elevation of plasma soluble human leukocyte antigen-G in patients with chronic hepatitis C virus infection. Hum Immunol (2011) 72:406-11. doi:10.1016/j.humimm.2011.02.008
145. Park Y, Lim HS, Kim YS, Hong DJ, Kim HS. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. Tissue Antigens (2012) 79:97-103. doi:10.1111/j.1399-0039.2011.01814.x
146. Shi WW, Lin A, Xu DP, Bao WG, Zhang JG, Chen SY, et al. Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection. Hum Immunol (2011) 72:1068-73. doi:10.1016/j.humimm.2011.06.012
147. Han Q, Li N, Zhu Q, Li Z, Zhang G, Chen J, et al. Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection. Clin Exp Med (2014) 14:35-43. doi:10.1007/s10238-012-0214-5
148. Amiot L, Vu N, Rauch M, L'Helgoualc'h A, Chalmel F, Gascan H, et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. J Hepatol (2014) 60:245-52. doi:10.1016/j.jhep.2013.09.006
149. Koller BH, Geraghty DE, Shimizu Y, DeMars R, Orr HT. HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. J Immunol (1988) 141:897-904.
150. Geraghty DE, Wei XH, Orr HT, Koller BH. Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element. J Exp Med (1990) 171:1-18. doi:10.1084/jem.171.1.1
151. Sullivan LC, Clements CS, Rossjohn J, Brooks AG. The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity. Tissue Antigens (2008) 72:415-24. doi:10.1111/j.1399-0039.2008.01138.x
152. Garcia P, Llano M, de Heredia AB, Willberg CB, Caparrós E, Aparicio P, et al. Human T cell receptor-mediated recognition of HLA-E. Eur J Immunol (2002) 32:936-44. doi:10.1002/1521-4141(200204)32:4<936::AID-IMMU936>3.3.CO;2-D
153. Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (1998) 391:795-9. doi:10.1038/35869
154. Carosella ED, Paul P, Moreau P, Rouas-Freiss N. HLA-G and HLA-E: fundamental and pathophysiological aspects. Immunol Today (2000) 21:532-4. doi:10.1016/S0167-5699(00)01707-2
155. Lee N, Ishitani A, Geraght DE. HLA-F is a surface marker on activated lymphocytes,". Eur J Immunol (2010) 40:2308-18. doi:10.1002/eji.201040348
156. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol (2003) 171:1376-84. doi:10.4049/jimmunol.171.3.1376
157. Fiszer D, Ulbrecht M, Fernandez N, Johnson JP, Weiss EH, Kurpisz M. Analysis of HLA class Ib gene expression in male gametogenic cells. Eur J Immunol (1997) 27:1691-5. doi:10.1002/eji.1830270715
158. Zhang X, Lin A, Zhang JG, Bao WG, Xu DP, Ruan YY, et al. Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma. Int J Cancer (2013) 132:82-9. doi:10.1002/ijc.27621
159. Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. Front Immunol (2014) 22(5):394. doi:10.3389/fimmu.2014.00394
160. Morandi F, Cangemi G, Barco S, Amoroso L, Giuliano M, Gigliotti AR, et al. Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients. Biomed Res Int (2013) 2013:956878. doi:10.1155/2013/956878
161. Morandi F, Venturi C, Rizzo R, Castellazzi M, Baldi E, Caniatti ML, et al. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. J Neuroimmune Pharmacol (2013) 8:944-55. doi:10.1007/s11481-013-9459-3